Tagged with

Bristol-Myers Squibb Brazil Two days ago, the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan against chronic diseases for when the UN next addresses the General Assembly in September. What would be your suggestions? If…

Boehringer Ingelheim B.V. While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general manager of this Dutch affiliate. What were some of the highlights of the past year and the main lessons that you look forward to carrying…

WestHolland Foreign Investment Agency (WFIA) WFIA is quite a remarkable organisation that has been, since its inception ten years ago, reporting very good results. The annual results last week showed another strong focus on the Life Sciences sector. What drives the agency to place so much effort on attracting investments in Life Sciences in the…

Eurofarma Your position unites two somewhat incongruous titles – Director of Sustainability, and New Business. How did this come to be, and what if any overlap is there between these two areas in Eurofarma? I’ve spent my whole career in marketing, beginning in direct-to-consumer marketing in OTCs. In the 2000s, when…

Takeda Italy Takeda has more than 25 years of history in Italy and reached the 20th position in the Italian market- a striking performance in a context when it is still rare to see Japanese companies being very successful in Europe, with such a different culture. Which main guidelines of the Italian…

Merck Sharp & Dohme (MSD) Malaysia Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger last year with Schering-Plough, MSD has been #1 in the ethical category and we carry a heavy responsibility to remain…

OEP Philippines Mr. Chang, can you please give an overview of the establishment of OEP Philippines and the company’s current activities here? OEP Philippines started by acquiring the operations of Elan Pharma Phils, an Irish company. In 2003, when Elan Pharma decided to dispose of their subsidiary in the Philippines, Mr. Peter…

Boehringer Ingelheim Brazil You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three years, my assignment was to open this company and to integrate it more with Brazil. We have a quite enlightened…

Boehringer Ingelheim Italy The main distinctive point of Boehringer Ingelheim Italy within the group is its business structure, which relies on three different units: Boehringer Ingelheim Spa, Bidachem and Istituto de Angeli. Could you describe the role of each entity together with its contribution to resources and growth? Boehringer Ingelheim itself is responsible…

Eli Lilly do Brasil An important topic in Brazil is access to drugs. In recent interviews we have spoken about a third of MS patients being treated, or 10% of hypertensives having their condition under control. With your predecessor Mr. Crupi in 2007 we compared the situation in Brazil to Canada, one of his…

Niaba The Netherlands is famous throughout Europe and the global pharmaceutical community for its research infrastructure – institutes, university hospitals, and public private partnerships. Given this foundation and the size of the country relative to larger biotech neighbors such as the UK, France, and Germany, how would you assess the strength…

AstraZeneca Brazil What have been some of the recent milestones and achievements contributing to AstraZeneca Brazil’s status as the country’s fastest growing MNC? What happened in the last 10 years was a very productive combination of excellent products being worked by talented people with the right level of investment. This is what…